Greenland Mines Ltd (NASDAQ: GRML) has announced a series of strategic milestones as it sharpens its focus on rare earths and critical minerals. The company plans to spin off its biotechnology division in the fourth quarter of 2026, a move that underscores its commitment to becoming a dedicated mining entity. This transition comes as the company resolves prior deficiencies with Nasdaq and completes the acquisition of the Sarfartoq project, which holds substantial neodymium-praseodymium (NdPr) resources.
Nasdaq has formally approved the company's application related to its March 2026 transaction, bringing Greenland Mines into full compliance with listing requirements. This approval resolves previous issues and ensures the company's continued presence on the exchange. The completion of the Sarfartoq acquisition on Sept. 1, following approval by the Government of Greenland, marks a significant step in the company's strategy to build a multi-asset platform with exposure to rare earth magnet materials and precious metals.
An independent S-K 1300 Initial Assessment for the ST1 deposit at Sarfartoq estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. The assessment highlights the project's potential to contribute significantly to the global supply chain for NdPr oxides, which are essential for permanent magnets used in electric vehicles and wind turbines. Planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining capacity outside China, based on 2025 consumption levels, during each of the project's nine scheduled operating years. This positions Greenland Mines as a potential key player in diversifying the supply chain away from China, which dominates the market.
The company is also reshaping its board to align with its new strategic direction. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project. This change brings fresh expertise to guide the company through its next phase of development.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, will allow Greenland Mines to focus entirely on its mining operations. The biotech division has been a separate part of the company, and its separation is expected to unlock value for shareholders by allowing each business to be valued independently. The company's strategy is centered on building a broader North Atlantic Critical Metals Corridor vision, linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
These developments are significant for the critical minerals sector, as they come at a time when Western nations are seeking to reduce reliance on Chinese rare earth processing. Greenland Mines' progress on Sarfartoq could contribute to a more secure supply chain for these essential materials. For more information on the company's news and updates, visit their newsroom at https://ibn.fm/GRML.
